Tissue factor – a therapeutic target for thrombotic disorders

Bibliography

• JENNY NS, MANN KG: Coagulation cascade: an overview. In: Thrombosis and Hemorrhage. Loscalzo J, Schafer Al (Eds), Williams & Wilkins, Baltimore, MD, USA (1998):3–27.
   Google Scholar
• DRAKE TA, MORRISSEY JH, EDGINGTON TS: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am. j Pathol (1989) 134:1087–1097.
   Google Scholar
• •The first careful analysis of the tissue and cellular distribution of TF, which was made possible by cloning the gene and preparing mAb. Introduces the notion of constitutively expressed TF as a 'haemostatic envelope'.
   Google Scholar
• MORRISSEY JH: Tissue factor and factor VII initiation of coagulation. In: Hemostasis, and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds.), Lippincott, Williams &Wilkins, Philadelphia, PA, USA (2001):89–101.
   Google Scholar
• DRAKE TA, RUF W, MORRISSEY JH, EDGINGTON TS: Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. j Cell Biol. (1989) 109:389–395.
   PubMed Web of Science ®Google Scholar
• VAN'T VEER C, MANN KG: Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III and heparin cofactor-II. _J. Biol. Chem. (1997) 272:4367–4377.
   PubMed Web of Science ®Google Scholar
• GRIGNANI G, MAIOLO A: Cytokines and hemostasis. Haematologica (2000) 85:967–972.
   PubMed Web of Science ®Google Scholar
• NEUMANN FJ, OTT I, MARX N etal.: Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler. Thromb. Vasc. Biol. (1997) 17:3399–3405.
   Google Scholar
• NAKAGOMI A, FREEDMAN SB, GECZY CL: Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex and hormone replacement treatment. Circulation (2000) 101:1785–1791.
   PubMed Web of Science ®Google Scholar
• ERNOFSSON M, SIEGBAHN A: Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb. Res. (1996) 83:307–320.
   PubMed Web of Science ®Google Scholar
• KHAJURIA A, HOUSTON DS: Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood (2000) 96:966–972.
   PubMed Web of Science ®Google Scholar
• •Physiologically relevant concentrations of homocysteine induce expression of TF by monocytes, which may explain the thrombotic diathesis associated with hyperhomocysteinaemia.
   Google Scholar
• WAUTIER MP, CHAPPEY O, CORDA S et al.: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. Physiol. Endocrinol Metab. (2001) 280:E685–E694.
   Web of Science ®Google Scholar
• LYBERG T, PRYDZ H: Thromboplastin (Factor III) activity in human monocytes induced by immune complexes. Eur. j Chu. Invest. (1982) 12:229–234.
   PubMed Web of Science ®Google Scholar
• CERMAK J, KEY NS, BACH RR et a/.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood (1993) 82:513–520.
   Google Scholar
• SU SJ, YEH TM: Effects of alpha 1-acid glycoprotein on tissue factor expression and tumor necrosis factor secretion in human monocytes. Immurropharmacology (1996) 34:139–145.
   PubMedGoogle Scholar
• LAWSON CA, YAN SD, YAN SF et al: Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Chu. Invest. (1997) 99:1729–1738.
   PubMed Web of Science ®Google Scholar
• HEYDERMAN RS, KLEIN NJ, DARAMOLA OA, LEVIN M: Modulation of the endothelial procoagulant response to lipopolysaccharide and tumour necrosis factor-alpha in-vitro: the effects of dexamethasone, pentoxifylline, iloprost and a polyclonal antihuman IL-1 alpha antibody. Inllamm. Res. (1995) 44:275–280.
   PubMed Web of Science ®Google Scholar
• ERLICH J, FEARNS C, MATHISON J, ULEVITCH RJ, MACKMAN N: Lipopolysaccharide induction of tissue factor expression in rabbits. Infect. Immun. (1999) 67:2540–2546.
   PubMed Web of Science ®Google Scholar
• DRAKE TA, CHENG J, CHANG A, TAYLOR FB JR: Expression of tissue factor, thrombomodulin and E-selectin in baboons with lethal Escherichia coil sepsis. Am. Pathol (1993) 142:1458–1470.
   PubMed Web of Science ®Google Scholar
• SEMERARO N, TRIGGIANI R, MONTEMURRO P, CAVALLO LG, COLUCCI M: Enhanced endothelial tissue factor but normal thrombomodulin in endotoxin-treated rabbits. Thromb. Res. (1993) 71:479–486.
   PubMed Web of Science ®Google Scholar
• RIVERS RPA, CATTERMOLE HEJ, WRIGHT I: The expression of surface tissue factor apoprotein by blood monocytes in the course of infections in early infancy. Fed Res. (1992) 31:567–573.
   Google Scholar
• OSTERUD B, FLAEGSTAD T: Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb. Haemost. (1983) 49:5–7.
   PubMed Web of Science ®Google Scholar
• •An early study showing the relationship between sepsis, monocyte TF expression and DIC.
   Google Scholar
• KEY NS, SLUNGAARD A, DANDELET L etal.: Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood (1998) 91:4216–4223.
   Google Scholar
• ••Description of an assay for TF activity inwhole blood (almost all of which is attributable to monocytes). Since the blood can be frozen at collection, without isolation of cells, this type of assay should facilitate elucidation of the importance of circulating TF in epidemiologic studies.
   Google Scholar
• AL SAADY NM, LEATHAM EW, GUPTA S et al.: Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart (1999) 81:134–140.
   PubMed Web of Science ®Google Scholar
• SALIOLA M, LORENZET R, FERRO D et al: Enhanced expression of monocyte tissue factor in patients with liver cirrhosis. Cut (1998) 43:428–432.
   Google Scholar
• OSTERUD B, DUE J JR: Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes. Scant/. Haentatol (1984) 32:258–264.
   Google Scholar
• NYGAARD OP, UNNEBERG K, REIKERAS O, OSTERUD B: Thromboplastin activity of blood monocytes after total hip replacement. Scand. Clin. Lab. Invest. (1990) 50:183–186.
   PubMed Web of Science ®Google Scholar
• CARSON SD, HAIRE WD, BROZE GJ JR et al: Lipoprotein associated coagulation inhibitor, factor VII, antithrombin III and monocyte tissue factor following surgery. Thromb. Haemost. (1991) 66:534–539.
   PubMed Web of Science ®Google Scholar
• MILLER CL, GRAZIANO C, LIM RC, CHIN M: Generation of tissue factor by patient monocytes: correlation to thromboembolic complications. Thromb. Haemost. (1981) 46:489–495.
   PubMed Web of Science ®Google Scholar
• OTT I, ANDRASSY M, ZIEGLGANSBERGER D et al: Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. Blood (2001) 97:3721–3726.
   PubMed Web of Science ®Google Scholar
• FREEBURN JC, WALLACE JM, STRAIN JJ et al.: Monocyte tissue factor-like activity in post myocardial infarction patients. Br j Haentatol (1998) 102:605–608.
   PubMed Web of Science ®Google Scholar
• FRANCO RF, DE JONGE E, DEKKERS PE et al: The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood (2000) 96:554–559.
   PubMed Web of Science ®Google Scholar
• REVERTER JC, TASSIES D, FONT J et al.: Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler. Thromb. Vase. Biol. (1996) 16:1319–1326.
   PubMed Web of Science ®Google Scholar
• •Induction of monocyte TF expression may explain at least a part of the thrombotic diathesis associated with the antiphospholipid antibody syndrome. This offers the possibility of developing targeted therapeutic interventions for a condition in which conventional anticoagulants frequently fail.
   Google Scholar
• POUPLARD C, IOCHMANN S, RENARD B et al: Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood (2001) 97:3300–3302.
   PubMed Web of Science ®Google Scholar
• JUDE B, AGRAOU B, MCFADDEN EP et al.: Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or stable angina. Circulation (1994) 90:1662–1668.
   PubMed Web of Science ®Google Scholar
• LEATHAM EW, BATH PMW, TOOZE JA, CAMM AJ: Increased monocyte tissue factor expression in coronary disease. Br Heart. j (1995) 73:10–13.
   PubMedGoogle Scholar
• SANTUCCI RA, ERLICH J, LABRIOLA J et al.: Measurement of tissue factor activity in whole blood. Thromb. Haemost. (2000) 83:445–454.
   PubMed Web of Science ®Google Scholar
• LEE WH, LEE Y, KIM JR etal.: Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients. Esp. Mal Med. (1999) 31:159–164.
   Google Scholar
• KAPPELMAYER J, BERECKI D, MISZ M et al: Monocytes express tissue factor in young patients with cerebral ischemia. Cerebrovasc. Dis. (1998) 8:235–239.
   PubMed Web of Science ®Google Scholar
• FALCIANI M, GORI AM, FEDI S et al:Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb. Haemost. (1998) 79:495–499.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA K, OGAWA H, YASUE H et al.: Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. jun Circ. (1998) 62:710–712.
   Web of Science ®Google Scholar
• GANDO S, NANZAKI S, SASAKI S, KEMMOTSU O: Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb. Haemost. (1998) 79:1111–1115.
   PubMed Web of Science ®Google Scholar
• ARNAUD E, BARBALAT V, NICAUD V et al.: Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris Thrombosis Case-Control Study. Arterioscler. Thromb. Vasc. Biol. (2000) 20:892–898.
   PubMed Web of Science ®Google Scholar
• FUSTER V, BADIMON J, CHESEBRO JH, FALLON JT: Plaque rupture, thrombosis and therapeutic implications. Haemostasis (1996) 26\(Suppl. 4):269–284.
   Google Scholar
• TAUBMAN MB, GIESEN PL, SCHECTER AD, NEMERSON Y: Regulation of the procoagulant response to arterial injury. Thromb. Haemost. (1999) 82:801–805.
   PubMed Web of Science ®Google Scholar
• KAIKITA K, OGAWA H, YASUE H et al: Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2232–2237.
   PubMed Web of Science ®Google Scholar
• ••Important evidence for the role of TF inatherosclerotic plaques in the pathogenesis of unstable angina.
   Google Scholar
• MORRISSEY JH: Tissue factor: an enzyme cofactor and a true receptor. Thromb. Haemost. (2001) 86:66–74.
   PubMed Web of Science ®Google Scholar
• ABE K, SHOJI M, CHEN J et al: Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl. Acad. Sci. USA (1999) 96:8663–8668.
   PubMed Web of Science ®Google Scholar
• RAO LV: Tissue factor as a tumor procoagulant. Cancer Metastasis Rev (1992) 11:249–266.
   PubMed Web of Science ®Google Scholar
• MUELLER BM, REISFELD RA, EDGINGTON TS, RUF W: Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc. Natl. Acad. Sci. USA (1992) 89:11832–11836.
   PubMed Web of Science ®Google Scholar
• MUELLER BM, RUF W: Requirement forbinding of catalytically active Factor VIIa in tissue factor-dependent experimental metastasis. J. Chu. Invest. (1998) 101:1372–1378.
   PubMed Web of Science ®Google Scholar
• BROMBERG ME, SUNDARAM R, HOMER RJ, GAREN A, KONIGSBERG WH: Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb. Haemost. (1999) 82:88–92.
   PubMed Web of Science ®Google Scholar
• SETO S, ONODERA H, KAIDO T et al:Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer (2000) 88:295–301.
   PubMed Web of Science ®Google Scholar
• SHIGEMORI C, WADA H, MATSUMOTO K et al.: Tissue factor expression and metastatic potential of colorectal cancer. Thromb. Haemost. (1998) 80:894–898.
   PubMed Web of Science ®Google Scholar
• JOHNSON MJ, SPROULE MW, PAUL J: The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Chu. arca (R. Coll. Radial) (1999) 11:105–110.
   PubMed Web of Science ®Google Scholar
• FALANGA A, DONATI MB: Pathogenesis of thrombosis in patients with malignancy. Int. Hematol. (2001) 73:137–144.
   PubMed Web of Science ®Google Scholar
• PARMAR J, TAYLOR I, ROATH S, FRANCIS J: Procoagulant activity in whole blood from patients with breast and colorectal cancer. Blood Coagul Fibrinolysis (1990) 1:127–132.
   PubMedGoogle Scholar
• LWALEED BA, CHISHOLM M, FRANCIS JL: Urinary tissue factor levels in patients with breast and colorectal cancer. Pathol (1999) 187:291–294.
   Web of Science ®Google Scholar
• EDWARDS RL, RICKLES FR, CRONLUND M: Abnormalitites of blood coagulation in patients with cancer. j Lab. Chu. Med. (1981) 98:917–928.
   PubMed Web of Science ®Google Scholar
• LWALEED BA, FRANCIS JL, CHISHOLM M: Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression. EN Int. (1999) 83:476–482.
   Google Scholar
• VIERO P, CORTELLAZZO S, CASAROTTO C et al: Increased production of mononuclear cell procoagulant activity in Hodgkin's disease. Eur. J. Cancer Chu. arca (1983) 19:1539–1543.
   Web of Science ®Google Scholar
• HAIRE WD, PIRRUCCELLO SJ, CARSON SD: Monocyte tissue factor in treated Hodgkin's disease. Leuk. Lymphoma (1994) 12:259–263.
   PubMed Web of Science ®Google Scholar
• DOUKETIS JD, FOSTER GA, CROWTHER MA, PRINS MH, GINSBERG JS: Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch. Intern. Med. (2000) 160:3431–3436.
   PubMed Web of Science ®Google Scholar
• PALARETI G, LEGNANI C, LEE A et al: A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb. Haemost. (2000) 84:805–810.
   PubMed Web of Science ®Google Scholar
• VALENTINE KA, HULL RD, PINEO GF: Low-molecular-weight heparin therapy and mortality. Semi]. Thromb. Hemost. (1997) 23:173–178.
   PubMed Web of Science ®Google Scholar
• PRADIER O, GERARD C, DELVAUX A et al.: Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur. Immurrol (1993) 23:2700–2703.
   PubMed Web of Science ®Google Scholar
• LINDMARK E, TENNO T, CHEN J, SIEGBAHN A: IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood. Br j Haematol (1998) 102:597–604.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, SAVI P, LAPLACE MC et al: IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett. (1993) 328:268–270.
   PubMed Web of Science ®Google Scholar
• OSNES LT, WESTVIK AB, J00 GB, OKKENHAUG C, KIERULF P: Inhibition of IL-1 induced tissue factor (T9 synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13. Cytokine (1996) 8:822–827.
   PubMed Web of Science ®Google Scholar
• ERNOFSSON M, TENNO T, SIEGBAHN A: Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines. Br Haematol (1996) 95:249–257.
   PubMed Web of Science ®Google Scholar
• CRUTCHLEY DJ, HIRSH MJ: The stableprostacyclin analog, iloprost and prostaglandin El inhibit monocyte procoagulant activity in vitro. Blood (1991) 78:382–386.
   PubMed Web of Science ®Google Scholar
• LYBERG T: Effect of cyclic AMP and cyclic GMP on thromboplastin (factor III) synthesis in human monocytes in vitro. Thromb. Haemost. (1983) 50:804–809.
   PubMed Web of Science ®Google Scholar
• DE PROST D, OLLIVIER V, HAKIM J: Pentoxifylline inhibition of procoagulant activity generated by activated mononuclear phagocytes. Mal Pharmacol (1990) 38:562–566.
   PubMed Web of Science ®Google Scholar
• LEVI M, TEN CATE H, BAUER KA et al.: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. Clirr. Invest. (1994) 93:114–120.
   PubMed Web of Science ®Google Scholar
• SUSEN S, HAZZAN M, LABALETTE M et al.: Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications. Thromb. Haemost. (2000) 84:764–769.
   PubMed Web of Science ®Google Scholar
• •A clinical trial showing that pentoxifylline inhibits the rise in monocyte TF expression that occurs shortly after organ transplantation.
   Google Scholar
• KOYAMA T, SHIBAKURA M, OHSAWA M, KAMIYAMA R, HIROSAWA S: Anticoagulant effects of lalpha, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood (1998) 92:160–167.
   PubMed Web of Science ®Google Scholar
• OHSAWA M, KOYAMA T, YAMAMOTO K etal.: la,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation (2000) 102:2867–2872.
   Google Scholar
• ASAKURA H, AOSHIMA K, SUGA Y et al: Beneficial effect of the active form of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models. Thromb. Haemost. (2001) 85:287–290.
   PubMed Web of Science ®Google Scholar
• BARSTAD RM, HAMERS MJ, STEPHENS RW, SAKARIASSEN KS: Retinoic acid reduces induction of monocyte tissue factor and tissue factor/ factor VIIa-dependent arterial thrombus formation. Blood (1995) 86:212–218.
   PubMed Web of Science ®Google Scholar
• OETH P, YAO J, FAN ST, MACKMAN N: Retinoic acid selectively inhibits lipopolysaccharide induction of tissue factor gene expression in human monocytes. Blood (1998) 91:2857–2865.
   PubMed Web of Science ®Google Scholar
• BOTTLES KD, MORRISSEY JH: Dexamethasone enhances agonist induction of tissue factor in monocytes but not in endothelial cells. Blood Coagul Fibrinolysis (1993) 4:405–414.
   PubMed Web of Science ®Google Scholar
• NAPOLEONE E, DI SANTO A, CAMERA M, TREMOLI E, LORENZET R: Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ. Res. (2000) 86:139–143.
   PubMed Web of Science ®Google Scholar
• NAGATA K, ISHIBASHI T, SAKAMOTO T etal.: Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. Hyperteris. (2001) 19:775–783.
   Google Scholar
• SOEJIMA H, OGAWA H, YASUE H et aL: Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. I Am. Coll. Cardiol. (1999) 34:983–988.
   PubMed Web of Science ®Google Scholar
• COLLI S, ELIGINI S, LALLI M et al.: Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. (1997) 17:265–272.
   PubMed Web of Science ®Google Scholar
• FERRO D, BASILI S, ALESSANDRI C, CARA D, VIOLI F: Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis (2000) 149:111–116.
   PubMed Web of Science ®Google Scholar
• HOLSCHERMANN H, HILGENDORFF A, KEMKES-MATTHES B et al.: Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation (2000) 69:1830–1836.
   PubMed Web of Science ®Google Scholar
• STEPHENS AC, RIVERS RP: Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide. Thromb. Res. (1997) 85:387–398.
   PubMed Web of Science ®Google Scholar
• BOHRER H, QIU F, ZIMMERMANN T et al.: Role of NF-KB in the mortality of sepsis. J. OM. Invest. (1997) 100:972–985.
   PubMed Web of Science ®Google Scholar
• ••An impressive demonstration in a mousemodel of sepsis of the potential benefits of gene transfer therapy. Two plasmid constructs were administered intravenously before endotoxin challenge. One expressed IkB, an inhibitor of NF-kB, which is one of the key transcription factors involved in the inducible expression of TE The other expressed an antisense sequence to the TF gene. Both constructs reduced markers activation of coagulation and both improved survival.
   Google Scholar
• ZHANG Y, DENG Y, WENDT T et al.: Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth-A sarcoma. OM. Invest. (1996) 97:2213–2224.
   PubMed Web of Science ®Google Scholar
• OSTERUD B: The role of platelets in decrypting monocyte tissue factor. Semin. Hematol. (2001) 38:2–5.
   PubMed Web of Science ®Google Scholar
• ••A good review of a topic that remainscomplex but is likely of considerable importance: the intercellular interactions that regulate monocyte activation and TF expression.
   Google Scholar
• HALVORSEN H, OLSEN JO, OSTERUD B: Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets. j Leukoc. Biol. (1993) 54:275–282.
   PubMed Web of Science ®Google Scholar
• OSTERUD B: Platelet activating factor enhancement of lipopolysaccharide-induced tissue factor activity in monocytes: requirement of platelets and granulocytes. Leukoc. Biol. (1992) 51:462–465.
   PubMed Web of Science ®Google Scholar
• GIESEN PL, RAUCH U, BOHRMANN B et al.: Blood-borne tissue factor: another view of thrombosis. Proc. Nati Acad. Sri. USA (1999) 96:2311–2315.
   PubMed Web of Science ®Google Scholar
• •Demonstration that monocyte-derived TF may play a role in thrombus formation in flowing blood.
   Google Scholar
• PRESTA L, SIMS P, MENG YG et al.: Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb. Haemost. (2001) 85:379–389.
   PubMed Web of Science ®Google Scholar
• PAWASHE AB, GOLINO E AMBROSIO G et al.: A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ. Res. (1994) 74:56–63.
   Google Scholar
• JANG IK, GOLD HK, LEINBACH RC et al.: Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler. Thromb. (1992) 12:948–954.
   PubMedGoogle Scholar
• TAYLOR FB JR, CHANG A, RUF W et al.: Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock (1991) 33:127–134.
   Google Scholar
• ••A key demonstration in a baboon model ofthe value of blocking the TF pathway in sepsis.
   Google Scholar
• BIEMOND BJ, LEVI M, TEN CATE H etal.: Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb. Haemost. (1995) 73:223–230.
   Google Scholar
• DICKINSON CD, RUF W: Active site modification of factor VIIa affects interactions of the protease domain with tissue factor. j Biol. Chem. (1997) 272:19875–19879.
   PubMed Web of Science ®Google Scholar
• RAO LV, EZBAN M: Active site-blocked activated factor VII as an effective antithrombotic agent: mechanism of action. Blood Cavil]. Fibririolysis (2000) 11\(Suppl. 1):5135–5143.
   Google Scholar
• GOLINO E RAGNI M, CIRILLO P et al.: Antithrombotic effects of recombinant human, active site-blocked Factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ. Res. (1998) 82:39–46.
   Google Scholar
• GOLINO E RAGNI M, CIRILLO P et al.: Recombinant human, active site-blocked Factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. Am. Physiol. Heart Circ. Physiol. (2000) 278:H1507–H1516.
   Google Scholar
• JANG Y, GUZMAN LA, LINCOFF AM et al.: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation (1995) 92:3041–3050.
   PubMed Web of Science ®Google Scholar
• ••A valuable attempt to compare the efficacyof intervention at different steps in the coagulation cascade in preventing restenosis after arterial injury in a rabbit model. Inhibition of coagulation at the level of TF/EVIIa by either of two agents (FVIIai or TERI) was more effective than inhibition at the level of FXa or at the level of thrombin.
   Google Scholar
• COURTMAN DW, SCHWARTZ SM, HART CE: Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass. Extrinsic pathway inhibition eliminates luminal narrowing. Circ. Res. (1998) 82:996–1006.
   Google Scholar
• HARKER LA, HANSON SR, WILCOX JN, KELLY AB: Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis (1996) 26\(Suppl. 1):76–82.
   Google Scholar
• HEDNER U, ERHARDTSEN E: Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI. Ann. Med. (2000) 32 (Suppl. 1):68–72.
   Google Scholar
• ARNLJOTS B, EZBAN M, HEDNER U: Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. j Vasc. &mg. (1997) 25:341–346.
   PubMed Web of Science ®Google Scholar
• HOLST J, KRISTENSEN AT, KRISTENSEN HI, EZBAN M, HEDNER U: Local application of recombinant active-site inhibited human clotting Factor VITa reduces thrombus weight and improves patency in a rabbit venous thrombosis model. Eur. j Vasc. Endovasc. &lig. (1998) 15:515–520.
   PubMed Web of Science ®Google Scholar
• Endarterectomy for asymptomatic carotid artery stenosis. Executive committee for the asymptomatic carotid atherosclerosis study. JAMA (1995) 273:1421–1428.
   PubMed Web of Science ®Google Scholar
• BARNETT HJ, TAYLOR DW, ELIASZIW M etal.: Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American symptomatic carotid endarterectomy trial collaborators. N Engl. J. Med. (1998) 339:1415–1425.
   Google Scholar
• TAYLOR FB, CHANG AC, PEER G et al: Active site inhibited factor VITa (DEGR Vila) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coil. Blood (1998) 91: 1609-1615.
   Google Scholar
• WELTY-WOLF KE, CARRAWAY MS, MILLER DL et al.: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am. J. Respir. Gilt. Care Med. (2001) 164:1988–1996.
   PubMed Web of Science ®Google Scholar
• BAJAJ MS, BIRKTOFT JJ, STEER SA, BAJAJ SP: Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost. (2001) 86:959–972.
   PubMed Web of Science ®Google Scholar
• BROZE GJ JR: Tissue factor pathway inhibitor gene disruption. Blood Cavil]. Fibrinolysis (1998) 9\(Suppl. 1):589–592.
   Google Scholar
• ARIENS RA, ALBERTO G, MOTA M, MANNUCCI PM: Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb. Haemost. (1999) 81:203–207.
   PubMed Web of Science ®Google Scholar
• WESTRICK RJ, BODARY PF, XU Z et al.: Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation (2001) 103:3044–3046.
   PubMed Web of Science ®Google Scholar
• ALTMAN R, SCAZZIOTA A, ROUVIER J: Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor. Haemostasis (1998) 28:229–235.
   PubMedGoogle Scholar
• ABILDGAARD U, LINDAHL AK, SANDSET PM: Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis (1991) 21:254–257.
   PubMedGoogle Scholar
• HANSEN JB, SANDSET PM, HUSEBY KR, HUSEBY NE, NORDOY A: Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb. Haemost. (1996) 76:703–709.
   PubMed Web of Science ®Google Scholar
• THEROUX P, WATERS D, LAM J, JUNEAU M, MCCANS J: Reactivation of unstable angina after the discontinuation of heparin. N Engl. J. Med. (1992) 327:141–145.
   PubMed Web of Science ®Google Scholar
• HANSEN JB, SANDSET PM, HUSEBY KR et al.: Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br. j Haematol (1998) 101:638–646.
   PubMed Web of Science ®Google Scholar
• GIRAUX JL, TAPON-BRETAUDIERE J, MATOU S, FISCHER AM: Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells. Thromb. Haemost. (1998) 80:692–695.
   PubMed Web of Science ®Google Scholar
• HOPPENSTEADT DA, FAREED J, RAAKE P, RAAKE W: Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates. Thromb. Res. (2001) 103:157–163.
   PubMed Web of Science ®Google Scholar
• GLUSA E, BARTHEL W, SCHENK J et al.: Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters. Haemostasis (1998) 28:45–56.
   PubMedGoogle Scholar
• KAISER B, FAREED J: Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb. Haemost. (1996) 76:615–620.
   PubMed Web of Science ®Google Scholar
• HOLST J, LINDBLAD B, BERGQVIST D et al: Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis-a comparison with low molecular weight heparin. Thromb. Haemost. (1994) 71:214–219.
   PubMed Web of Science ®Google Scholar
• ROQUE M, REIS ED, FUSTER V et al: Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J. Am. Coll. Cardiol (2000) 36:2303–2310.
   PubMed Web of Science ®Google Scholar
• OLTRONA L, SPEIDEL CM, RECCHIA D et al.: Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation (1997) 96:646–652.
   PubMed Web of Science ®Google Scholar
• ST PIERRE J, YANG LY, TAMIRISA K et al.: Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler. Thromb. V3SC. Biol. (1999) 19:2263–2268.
   Google Scholar
• KHOURT RK, KOUDST B, KAIDING E ORNBERG RL, WUN TC: Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann. Plast. &lig. (1993) 30:398–402.
   PubMed Web of Science ®Google Scholar
• LANTIERT LA, OZBEK MR, DEUNE EG et al.: Prevention of microvascular thrombosis by topical application of recombinant tissue factor pathway inhibitor. Plast. Reconstr. (1996) 97:587–594.
   PubMed Web of Science ®Google Scholar
• KHOURT RK, SHERMAN R, BUNCKE HJ JR et al: A Phase II trial of intraluminal irrigation with recombinant human tissue factor pathway inhibitor to prevent thrombosis in free flap surgery. Plast. Reconstr. &lig. (2001) 107:408–415.
   PubMed Web of Science ®Google Scholar
• ••An important study proving thetherapeutic potential of the local application of TF antagonists. Perfusion of a tissue flap with TFPI before microvascular reanastomosis prevented thrombosis, without causing bleeding.
   Google Scholar
• SUN LB, UTOH J, MORTYAMA S et al: Pretreatment of a Dacron graft with tissue factor pathway inhibitor decreases thrombogenicity and neointimal thickness: a preliminary animal study. ASAIO (2001) 47:325–328.
   PubMed Web of Science ®Google Scholar
• SUN LB, UTOH J, MORTYAMA S et al: Topically applied tissue factor pathway inhibitor reduced intimal thickness of small arterial autografts in rabbits. J. Vasc. (2001) 34:151–155.
   PubMed Web of Science ®Google Scholar
• CREASEY AA, CHANG AC, FEIGEN L et al.: Tissue factor pathway inhibitor reduces mortality from Eschotichia coliseptic shock. J. Clin. Invest (1993) 91:2850–2856.
   PubMed Web of Science ®Google Scholar
• •Another key demonstration in this baboon sepsis model of the importance of the TF pathway in septic shock and DIC.
   Google Scholar
• CARR C, BILD GS, CHANG AC et al.: Recombinant E. coll-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock. Circ. Shock (1994) 44:126–137.
   Google Scholar
• RANDOLPH MM, WHITE GL, KOSANKE SD et al.: Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coil - a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coil. Thromb. Haemost. (1998) 79:1048–1053.
   Google Scholar
• GOLDFARB RD, GLOCK D, JOHNSON K et al.: Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock (1998) 10:258–264.
   PubMed Web of Science ®Google Scholar
• CAMEROTA AJ, CREASEY AA, PATLA V, LARKIN VA, FINK MP: Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with Gram-negative peritonitis. j Infect. Dis. (1998) 177:668–676.
   Google Scholar
• MATYAL R, VIN Y, DELUDE RL et al.: Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock. Interis. Care Med. (2001) 27:1274–1280.
   PubMed Web of Science ®Google Scholar
• DE JONGE E, DEKKERS PE, CREASEY AA et al.: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the flbrinolytic and cytokine response during human endotoxemia. Blood (2000) 95:1124–1129.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, REINHART K, SVOBODA P et al.: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Grit. Care Med. (2001) 29:2081–2089.
   PubMed Web of Science ®Google Scholar
• ••A pivotal preliminary trial of TFPI in patients with septic shock, demonstrating safety, biological activity and a trend to improvement in survival.
   Google Scholar
• DENNIS MS, LAZARUS RA: Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. _J. Biol. Chem. (1994) 269:22137–22144.
   Google Scholar
• GIRARD TJ, MACPHAIL LA, LIKERT KM et al.: Inhibition of Factor VIIa-tissue factor coagulation activity by a hybrid protein. Science (1990) 248:1421–1424.
   PubMed Web of Science ®Google Scholar
• LEE GE LAZARUS RA, KELLEY RF: Potent bifunctional anticoagulants: Kunitz domain-tissue factor fusion proteins. Biochemistry (1997) 36:5607–5611.
   PubMed Web of Science ®Google Scholar
• BREGENGARD C, NORDFANG 0, WILDGOOSE P et al.: The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul. Fibrinolysis (1993) 4:699–706.
   Google Scholar
• STANSSENS P, BERGUM PW, GANSEMANS Y et al.: Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc. Nati Acad. Sci. USA (1996) 93:2149–2154.
   PubMed Web of Science ®Google Scholar
• LEE A, AGNELLI G, BULLER H et al.: Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation (2001) 104:74–78.
   PubMed Web of Science ®Google Scholar
• •A Phase II clinical trial of NAPc2 in patients at high risk of deep vein thrombosis after orthopaedic surgery, demonstrating major activity.
   Google Scholar
• DENNIS MS, EIGENBROT C, SKELTON NJ et al.: Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature (2000) 404:465–470.
   PubMed Web of Science ®Google Scholar
• DENNIS MS, ROBERGE M, QUAN C, LAZARUS RA: Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa. Biochemistry (2001) 40:9513–9521.
   PubMed Web of Science ®Google Scholar
• JAKOBSEN P, PEDERSEN BR, PERSSON E: Inhibitors of the tissue factor/ factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel specific 2-aryl substituted 4H-3,1-benzoxazin-4-ones. Bioorg. Med.Chem. (2000) 8:2095–2103.
   PubMed Web of Science ®Google Scholar
• UCHIBA M, OKAJIMA K, ABE H, OKABE H, TAKATSUKI K: Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb.Res. (1994) 74:155–161.
   PubMed Web of Science ®Google Scholar
• HEIT JA, COLWELL CW, FRANCIS CW etal.: Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch. Intern. Med. (2001) 161:2215–2221.
   Google Scholar
• HIMBER J, KIRCHHOFER D, RIEDERER M et al.: Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb. Haemost. (1997) 78:1142–1149.
   PubMed Web of Science ®Google Scholar
• ••A worthwhile attempt to compare differentapproaches to anticoagulation with respect both to antithrombotic efficacy and haemorrhagic effect. A mAb to TF was equivalent to a direct thrombin inhibitor and better than heparin at preventing arterial thrombus formation. Heparin caused the most bleeding and the anti-TF antibody the least.
   Google Scholar